Floatz logo

gi-102

Colorectal Cancer

GI Innovation, Inc.Phase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

839 Active assets in the Colorectal Cancer cohort.

Asset / SponsorPhaseRating
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
MARBLE DUST
James Varani
Phase 2/3BB
Orectalip
Sinphar Pharmaceutical Co., Ltd
Phase 4BB
Eloxatin
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 4BB
FLUOROURACILUM
UNICANCER
Phase 4BB

View all 50 →

Same molecule, other indications

gi-102 is also rated in:

astrocytoma, IDH-mutant, grade 4Dormant
CCC
Indicative ·
53 / 100
View asset →
glioblastomaDormant
CCC
Indicative ·
53 / 100
View asset →
IDH-wildtype glioblastomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →